TriangleDT2216 (NCT06964009)
DT2216 trial for Platinum-Resistant Ovarian Cancer (NCT06964009). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for platinum-resistant ovarian cancer that has come back, in adults.
The idea: pair a protein degrader with chemotherapy. DT2216 is designed to break down BCL-XL, a protein that helps protect cancer cells from cell death. It is given by vein with weekly paclitaxel. Treatment runs in 28 day cycles, with imaging every two cycles.
This phase 1 study looks for the highest dose that can be given safely, and plans 30 patients. At Dana-Farber Cancer Institute in Boston, Elizabeth Stover leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.